Development
- Advanced Planning
-
Although the European and American approaches to pharmaceutical risk management differ slightly, both share the common objective of ensuring patient safety for marketed products.
- Streamlining Safety Data
-
With electronic data collection becoming more mainstream, clinical trialists are now looking to incorporate safety data into the electronic mix as well.
- Image Awareness
-
Radiological biomarkers hold the potential to be a positive force in pharmaceutical research, but the adoption of imaging techniques as a useful tool for drug development has been slow to materialize.
- Control Mechanism
-
A rapidly increasing rate of type 2 diabetes has researchers scrambling for new interventions to combat the chronic condition.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Asian Migration
-
Access to patients, lower costs and increased efficiencies are leading to an explosion in the amount of clinical research being conducted in Asia.
- Joining Forces
-
Global partnerships enable big pharma to streamline drug development and refocus their efforts on core competencies.
- The State of Stents
-
Drug-eluting stents have been under fire recently, but the medical community has yet to decide if the risks outweigh the rewards.
- Culture Shift
-
Drug safety monitoring needs to begin early in the development process and continue throughout the product’s entire lifecycle.
- A New Era Dawns
-
As the march toward universal electronic submission of regulatory documents continues, regulators and pharmaceutical manufacturers are learning how to best implement the new technology.
Web Exclusives
- An Unbalanced Burden
-
A Q&A with Dr. Kathleen Squires, director of the infectious disease department at Jefferson Medical College in Philadelphia, illuminates the gender differences in the diagnosis and treatment of HIV.
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.